Wellington Management Group LLP Invests $1.89 Million in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Wellington Management Group LLP purchased a new position in Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 14,314 shares of the medical instruments supplier's stock, valued at approximately $1,888,000. Wellington Management Group LLP owned 0.26% of Mesa Laboratories at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Deutsche Bank AG increased its stake in shares of Mesa Laboratories by 44.5% in the fourth quarter. Deutsche Bank AG now owns 5,147 shares of the medical instruments supplier's stock worth $679,000 after purchasing an additional 1,586 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Mesa Laboratories by 3.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,925 shares of the medical instruments supplier's stock worth $386,000 after purchasing an additional 98 shares in the last quarter. Sei Investments Co. increased its stake in shares of Mesa Laboratories by 246.2% in the fourth quarter. Sei Investments Co. now owns 5,411 shares of the medical instruments supplier's stock worth $714,000 after purchasing an additional 3,848 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Mesa Laboratories by 9.3% in the fourth quarter. Principal Financial Group Inc. now owns 38,359 shares of the medical instruments supplier's stock worth $5,058,000 after purchasing an additional 3,252 shares in the last quarter. Finally, Alliancebernstein L.P. increased its stake in shares of Mesa Laboratories by 2.6% in the fourth quarter. Alliancebernstein L.P. now owns 5,584 shares of the medical instruments supplier's stock worth $736,000 after purchasing an additional 141 shares in the last quarter. 90.60% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Mesa Laboratories news, CEO Gary M. Owens sold 21,000 shares of Mesa Laboratories stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the transaction, the chief executive officer now directly owns 43,337 shares of the company's stock, valued at $5,369,887.67. This trade represents a 32.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on MLAB shares. Wells Fargo & Company reduced their price objective on shares of Mesa Laboratories from $120.00 to $100.00 and set an "underweight" rating for the company in a research note on Friday, May 30th. Wall Street Zen cut shares of Mesa Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 30th.

Mesa Laboratories Price Performance

MLAB traded up $4.20 during trading on Friday, hitting $103.99. 290,440 shares of the company traded hands, compared to its average volume of 41,901. The company has a market cap of $567.27 million, a PE ratio of -2.25 and a beta of 0.88. The stock's 50-day simple moving average is $113.27 and its two-hundred day simple moving average is $125.94. Mesa Laboratories, Inc. has a 1 year low of $83.68 and a 1 year high of $155.12. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61.

Mesa Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, June 16th. Investors of record on Friday, May 30th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, May 30th. This represents a $0.64 annualized dividend and a yield of 0.62%. Mesa Laboratories's payout ratio is -172.97%.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.